The purpose of this study is to collect information on the: - general information of a group of people such as their age, sex, and other facts. - clinical information of the patients such as any other illness before having COVID 19.In adult patients with COVID-19 who have been prescribed nirmatrelvir and ritonavirtreatment.This study will be conducted in Morocco. The study will capture information of the adultCOVID-19 outpatients and inpatients who have been prescribed nirmatrelvir, ritonavirtreatment. The inpatients will be admitted in the hospital for other reasons thanCOVID-19.This study will have about 150 patients. The study will involve collection of patientinformation from medical records. The information collected can be either from papers orfrom computers.The study will include patient information of those who: - are confirmed to have COVID-19 infection during the study period from 01 June 2022 to 30 June 2023. - are 18 years of age or older. - are prescribed Nirmatrelvir and ritonavir. This study will help to inform decision-making on use of Paxlovid at the national level.
Not Provided
Drug: Nirmatrelvir/Ritonavir
Patients administered oral Paxlovid as prescribed according to national Morocco treatment
guidelines for Covid.
Other Name: Paxlovid
Inclusion Criteria:
- Confirmed COVID-19 infection during the study period from 01 June 2022 to 30 June
2023
- Nirmatrelvir, ritonavir written prescription
Exclusion Criteria:
- There are no exclusion criteria for this study.
Not Provided
Pfizer CT.gov Call Center, Study Director
Pfizer